Cardiac

Precordial Swirl (V1,2 ST elevation 1-2์นธ์œผ๋กœ mild, V5,6 ST depression 1-2์นธ์œผ๋กœ mild) = proximal LAD total occlusion

**lead 3 **ํ•˜๋‚˜๋งŒ ST elevation ์žˆ๊ณ (lead 2, aVR์€ ์ •์ƒ), **V4-6์—์„œ๋Š” ST depression** = RCA total occlusion, LAD partial occlusion ์œผ๋กœ multiple acute coronary occlusion์žˆ๋Š” ๊ฒฝ์šฐ

**Northeren OMI** = left main, proximal LAD occlusion ์œผ๋กœ heart base ischemia๋กœ ์‹ฌ์žฅ ์œ„์ชฝ lead ์ธ **aVR, aVL ST elevation,** ๋ฐ˜๋Œ€๋กœ inf ์ธ **lead 2,3,aVF ๋Š” ST depression** ์–‘์ƒ (์ด ๊ฒฝ์šฐ๋Š” ๋งค์šฐ ์ €๋ช…ํ•˜๊ฒŒ ๋ณด์ด์ง€๋งŒ, ์•ฝ๊ฐ„๋งŒ ๋ณด์ด๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์Œ)

normal LBBB
- ST elevation in lead aVR with diffuse ST depression in other leads โ†’ left main coranary a or proximal LAD dz
- post. wall myocardial infarction(PWMI) : R wave ์ฆ๊ฐ€, ST depression in V2-4
์ฃผ๋กœ post wall infaction ์žˆ์œผ๋ฉด, inf wall ์—๋„ ๋™๋ฐ˜๋˜์–ด V2-4 & lead 2,3,aVF elevation ๋ณด์ด๋Š”๋ฐ
V2-4 ST depression, V7-9 ST elevation ๋ณด์ž„

*post wall STEMI = V2-4 ST depression / post wall NSTEMI = V2-4 upsloping ST elevation * new tall T wave in V1 = post wall infarction * tall R wave in V6 = post wall infarction * ์ƒˆ๋กœ ์ƒ๊ธด RBBB + V1-6๊นŒ์ง€ ๋‹ค STE + v/s unstable = left main total infarction

โ†” ST elevation ์žˆ์–ด ๋ณด์ด์ง€๋งŒ, MI ๊ฐ€ ์•„๋‹Œ ๊ฒฝ์šฐ = LVH, LBBB, early repolarization, LV aneurysm,PSVT ๋“ฑ = ACS ๋Š” T/QRS ratio ๊ฐ€ ํฌ๋‹ค !!!!

QRS wave ๊ฐ€ ์ปค์ง€๋ฉด์„œ ๊ทธ์— ๋”ฐ๋ผ ๋”ฐ๋ผ์˜ค๋Š” T wave ๋„ ๋ฐ˜๋™์— ์˜ํ•ด ํฌ๊ธฐ๊ฐ€ ํฐ ๊ฒƒ

LBBB์žˆ๋Š” QRS ํฌ๊ธฐ๊ฐ€  ํฌ๋ฉด ACS ์•„๋‹Œ๋ฐ, LBBB ์˜ QRS ํฌ๊ธฐ๊ฐ€ ์ž‘์œผ๋ฉด์„œ ST elevation ์ด ์žˆ์œผ๋ฉด LBBB c ACS ์ธ ๊ฒƒ

early repolarization vs STEMI(QRS size ์ž‘์œผ๋ฉด์„œ ST elevation, ์ฆ‰ T/QRS ratio ๊ฐ€ ํฌ๋ฉด ACS ์ธ ๊ฒƒ)

PSVT ๋„ rate ๋น ๋ฅด๋ฉด์„œ diffuse ํ•˜๊ฒŒ ์˜ํ–ฅ์„ ๋ฐ›์€ ๊ฑฐ๋ผ, rate ์กฐ์ ˆ ํ•ด์ฃผ๋ฉด ๋œ๋‹ค,,

โ†’ Lasix (furosemide loop diuretics : ์ฒด๋‚ด ์ˆ˜๋ถ„ ์ œ๊ฑฐ, ์ด๋กœ ์ธํ•ด ์‹ ์žฅ ์ˆ˜์น˜ ๋‚˜๋น ์งˆ ์ˆ˜ ์žˆ์–ด ์ฃผ์˜ ํ•„์š”) โ†’ Dopamine(inotrope) : ์‹ฌ์žฅ ํŽŒํ”„ ๊ธฐ๋Šฅ ์˜ฌ๋ ค ์‹ ์žฅ์œผ๋กœ์˜ ํ˜ˆ๋ฅ˜ ์ฆ๊ฐ€, type 1,2 ๋“ฑ ์‹ฌ์žฅ ๋ฌธ์ œ์ธ ๊ฒฝ์šฐ ํšจ๊ณผ์  โ†’ ACEi, ARB : RAAS ์ฐจ๋‹จ์œผ๋กœ ์‹ ์žฅ ๋ณดํ˜ธ ํšจ๊ณผ ์žˆ์ง€๋งŒ, ๊ธ‰์„ฑ๊ธฐ ์‹œ ์‹ ์žฅ ์ˆ˜์น˜ ์ฆ๊ฐ€์‹œ์ผœ ๋งค์šฐ ์กฐ์‹ฌ์Šค๋Ÿฝ๊ฒŒ ์‚ฌ์šฉํ•ด์•ผ ํ•จ โ†’ SGLT2 inhibitor : ๋‹น๋‡จ์•ฝ์ด๋‚˜, ์‹ฌ๋ถ€์ „ ๋ฐ ๋งŒ์„ฑ ์‹ ๋ถ€์ „ ์ง„ํ–‰ ์–ต์ œ ํšจ๊ณผ ์žˆ๋‹ค๊ณ  ์•Œ๋ ค์ง